1. A Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

    Protocol
    08-091

    Full Title
    Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

    Phase
    I

    Purpose

    The purpose of this study is to find the highest dose of an investigational drug called perifosine that can be given safely in children with solid tumors that have returned or progressed despite prior therapy. Perifosine appears to block signals important in the development and growth of some cancers. It is taken orally (by mouth).

    Eligibility

    Read Full Article
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Authors